IVVDInvivyd, Inc.

$257M

FY 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$53M+110.5% YoY

Gross Profit

$50M93.0% margin

Operating Income

-$56M-104.0% margin

Net Income

-$52M-98.2% margin

EPS (Diluted)

$-0.30

Cash Flow

Operating Cash Flow

-$58M

Free Cash Flow

-$58M

Stock-Based Comp.

$12M

Balance Sheet

Total Assets

$277M

Total Liabilities

$35M

Stockholders' Equity

$242M

Cash & Equivalents

$227M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$53M	$25M	+110.5%
Gross Profit	$50M	$24M	+109.0%
Operating Income	-$56M	-$177M	+68.6%
Net Income	-$52M	-$170M	+69.1%

IVVD FY 2025 Earnings — Invivyd, Inc. Revenue & Financial Results | Market Cap Arena